Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. NYSE: MRK. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on April 9th.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Cummins NYSE: CMI on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Devon Energy NYSE: DVN on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Palantir Technologies NASDAQ: PLTR on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/8/2025.
Merck & Co., Inc. Price Performance
Shares of NYSE:MRK traded down $0.89 during midday trading on Tuesday, reaching $78.28. The company's stock had a trading volume of 16,039,392 shares, compared to its average volume of 11,584,687. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a market capitalization of $197.75 billion, a P/E ratio of 11.63, a P/E/G ratio of 0.77 and a beta of 0.40. Merck & Co., Inc. has a fifty-two week low of $75.96 and a fifty-two week high of $134.63. The business's fifty day simple moving average is $88.22 and its 200-day simple moving average is $97.04.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share for the quarter, missing analysts' consensus estimates of $1.85 by ($0.13). The business had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company's quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. As a group, equities research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.
Merck & Co., Inc. announced that its board has authorized a share buyback plan on Tuesday, January 28th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to repurchase up to 4.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
Merck & Co., Inc. Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, April 7th. Shareholders of record on Monday, March 17th were given a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 4.14%. The ex-dividend date was Monday, March 17th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 48.14%.
Insiders Place Their Bets
In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total transaction of $209,562.36. Following the transaction, the insider now owns 7,085 shares in the company, valued at approximately $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Inge G. Thulin acquired 2,833 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The shares were acquired at an average price of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares of the company's stock, valued at approximately $258,837.25. The trade was a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company's stock.
Analyst Ratings Changes
A number of brokerages have weighed in on MRK. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Leerink Partners cut their price target on Merck & Co., Inc. from $136.00 to $119.00 and set an "outperform" rating on the stock in a report on Monday, January 13th. Citigroup decreased their price objective on Merck & Co., Inc. from $125.00 to $115.00 and set a "buy" rating for the company in a report on Wednesday, February 5th. TD Securities cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their target price for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Finally, Truist Financial reaffirmed a "hold" rating and set a $110.00 price target (down from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $115.50.
Get Our Latest Research Report on MRK
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Franklin Resources Inc. raised its position in shares of Merck & Co., Inc. by 12.9% in the 3rd quarter. Franklin Resources Inc. now owns 16,049,161 shares of the company's stock worth $1,759,800,000 after acquiring an additional 1,836,505 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Merck & Co., Inc. by 1.9% during the 4th quarter. Janney Montgomery Scott LLC now owns 1,902,509 shares of the company's stock worth $189,262,000 after buying an additional 35,525 shares in the last quarter. Napatree Capital LLC increased its stake in shares of Merck & Co., Inc. by 13.0% in the 4th quarter. Napatree Capital LLC now owns 4,220 shares of the company's stock valued at $420,000 after acquiring an additional 485 shares in the last quarter. Littlejohn Financial Services Inc. bought a new position in Merck & Co., Inc. during the fourth quarter worth $2,080,000. Finally, Nordea Investment Management AB raised its holdings in shares of Merck & Co., Inc. by 4.7% during the fourth quarter. Nordea Investment Management AB now owns 9,399,643 shares of the company's stock valued at $933,761,000 after purchasing an additional 422,382 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.
Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.
About Merck & Co., Inc.
(
Get Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Recommended Stories
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
